<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112775">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02103166</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001921-19</org_study_id>
    <nct_id>NCT02103166</nct_id>
  </id_info>
  <brief_title>Role of Hyoscine Bromide in Latent and Active Labor</brief_title>
  <official_title>Randomized, Masked, Placebo-controlled Clinical Trial to Evaluate the Effects of a Single Intravenous Dose of Hyoscine Bromide on the Duration and Pain in Latent and Active Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hyoscine bromide decreases the duration of
      the active phase of labor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>Time to complete dilation</measure>
    <time_frame>One hour</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Labor, First Stage</condition>
  <arm_group>
    <arm_group_label>Hyoscine bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological serum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml of physiological serum (0.9% NaCl).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine bromide</intervention_name>
    <description>20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).</description>
    <arm_group_label>Hyoscine bromide</arm_group_label>
    <other_name>Buscapina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological serum</intervention_name>
    <description>100 ml of physiological serum (0.9% NaCl).</description>
    <arm_group_label>Physiological serum</arm_group_label>
    <other_name>Saline serum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 or more.

          -  Term pregnancy.

          -  Cephalic presentation.

          -  Oxytocin perfusion not present at the time of inclusion.

          -  Uterine dynamic established.

          -  Abscence of high risk factors or very high risk factors for pregnancy.

          -  Written informed consent

        Exclusion Criteria:

          -  Induction of labor.

          -  Presence of risk factors.

          -  Patients with hypersensitivity to the active substance or to any of the excipients or
             any contraindication reflected in technical report.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Montse Palacio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariona Rius, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Sandra Hernandez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Teixido, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Vives, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Midwives Collaborative Group HCP</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Montse Palacio, PhD</last_name>
    <phone>93 2279946</phone>
    <email>mpalacio@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montse Palacio, PhD</last_name>
      <phone>932279946</phone>
      <email>mpalacio@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Montse Palacio, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Montse Palacio</investigator_full_name>
    <investigator_title>MD, PhD.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
